Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
CORALVILLE, Iowa, Feb. 18, 2016 -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that its president and chief executive officer, Travis C. Mickle, Ph.D., will present at the RBC Capital Markets 2016 Healthcare Conference being held in New York, NY, February 23-24, 2016. Dr. Mickle will also present at the Cowen & Co. 36th Annual Health Care Conference 2016 being held in Boston, MA, March 7-9, 2016.
Details of KemPharm's presentations are as follows:
RBC Capital Markets 2016 Healthcare Conference
Date: Tuesday, February 23, 2016
Time: 3:35 PM (ET)
Location: The New York Palace Hotel in New York, NY
Cowen & Co. 36th Annual Health Care Conference 2016
Date: Monday, March 7, 2016
Time: 4:40 PM (ET)
Location: The Boston Marriott Copley Place in Boston, MA
The presentations will be webcast and available on the Investor Relations section of KemPharm's website at http://investors.kempharm.com/.
About KemPharm
KemPharm is a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its Ligand Activated Therapy (LAT) platform technology. KemPharm utilizes its LAT platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of pain, ADHD and other CNS disorders.
Investor Contacts: Jason Rando / Joshua Drumm, Ph.D. Tiberend Strategic Advisors, Inc. 212-375-2665 / 2664 [email protected] [email protected] Media Contact: Jim Heins Cooney Waters Unlimited 212-886-2221 [email protected]
